Citizens JMP analyst Silvan Tuerkcan reiterated a Buy rating on Terns Pharmaceuticals today and set a price target of $20.00. The company’s shares closed yesterday at $7.99.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Tuerkcan is a 4-star analyst with an average return of 6.5% and a 42.28% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Benitec Biopharma, Solid Biosciences, and IDEAYA Biosciences.
Terns Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $15.49.
TERN market cap is currently $737.7M and has a P/E ratio of -7.64.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TERN in relation to earlier this year. Earlier this month, Emil Kuriakose, the CMO of TERN sold 944.00 shares for a total of $7,400.96.
Read More on TERN:
Disclaimer & DisclosureReport an Issue
- Terns Pharmaceuticals initiated with an Overweight at Barclays
- Anticipated Data Updates and Underappreciated Catalysts Drive Buy Rating for Terns Pharmaceuticals
- Terns Pharmaceuticals assumed with a Neutral at H.C. Wainwright
- Terns Pharmaceuticals: A Promising Buy Amid Competitor Challenges in the Oral GLP-1 Space
- Disappointing competitor oral GLP-1 data an opportunity for Terns, says Mizuho
/AI%20(artificial%20intelligence)/AI%20engineer%20working%20on%20laptop%20by%20ART%20STOCK%20CREATIVE%20via%20Shutterstock.jpg)
/Nike%2C%20Inc_%20swish%20by-%20Tartezy%20via%20Shutterstock.jpg)